Compare TTI & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTI | SPTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1996 | 2026 |
| Metric | TTI | SPTX |
|---|---|---|
| Price | $8.45 | $22.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.40 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 92.7K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.70 | N/A |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | $66.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.82 | $17.59 |
| 52 Week High | $12.54 | $22.98 |
| Indicator | TTI | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 61.50 |
| Support Level | $7.71 | $18.72 |
| Resistance Level | $9.07 | $22.42 |
| Average True Range (ATR) | 0.57 | 1.41 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 64.37 | 86.46 |
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.